A Prospective, Single-arm Clinical Study of Pabrolizumab in Combination With Cisplatin + 5-FU for the Neoadjuvant Treatment of Unresectable, Advanced Squamous Carcinoma of the Temporal Bone Single-arm Clinical Study
Latest Information Update: 11 Jul 2022
At a glance
- Drugs Cisplatin (Primary) ; Fluorouracil (Primary) ; Pembrolizumab (Primary)
- Indications Bone cancer; Carcinoma; Head and neck cancer; Nasopharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 11 Jul 2022 New trial record